Health
LOTTE BIOLOGICS Announces Land Purchase Agreement with Incheon Free Economic Zone Authority, Establishing New Foothold in Songdo
* Construction of a Bio Plant with a total production capacity of 360 kL at Songdo's Block KI20, Zone 11 by 2030 * Aims to secure capabilities of an international standard and expand client base by making the Bio Plant a key hub SEOUL, South Korea, Oct. 4, 2023 /PRNewswire/ -- LOTTE BIOLOGICS...
2023-10-04 18:14
1589
Nuvilab Wins Most Innovative Food Recognition AI Company 2023
SEOUL, South Korea, Oct. 4, 2023 /PRNewswire/ -- Nuvilab, a leading food vision AI company, has been awarded Most Innovative Food Recognition AI Company 2023 in the International Life Sciences Awards, presented by Global Health & Pharma. The award recognizes Nuvilab's groundbreaking work in devel...
2023-10-04 15:22
1908
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical co...
2023-10-04 08:00
1502
First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial
SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first ...
2023-10-03 20:58
1968
Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study
- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after CBL-514 treatment. - Compared with placebo, an average of 312.1mL of subcutaneous fat was reduced in...
2023-10-02 21:00
1264
Flat Medical Secures Series C Funding Led by Taiwania Capital, Poised for Global Market Expansion
TAIPEI, Oct. 2, 2023 /PRNewswire/ -- Flat Medical, the leading medtech company specializing in innovative safety solutions for anesthesia, pain medicine, critical care and emergency medicine, is thrilled to announce the successful closing of its Series C funding round. The round was led by renown...
2023-10-02 20:30
1634
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), on receiving U.S. FDA's approval for Pombili...
2023-10-02 08:30
1389
Health In Tech, AMPS, and Drexi Host a Special Happy Hour Event at SIIA Conference
STUART, Fla., Sept. 29, 2023 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and re-imagines self-funded health plans, is thrilled to announce a collaborative Happy Hour event with industry leaders AMPS and Drexi. This event, scheduled du...
2023-09-29 22:18
2692
Akeso and RemeGen Collaborate on Clinical Study Exploring the Potential of PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combination Therapy in Gastric Cancer
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso's globally first PD-1/CTLA-4 bispecific antibody, cadonilimab ...
2023-09-29 20:00
2875
Jin Medical International Limited Receives NASDAQ Notification Letter Regarding Noncompliance with Continued Listing Rule 5550(a)(3)
CHANGZHOU, China, Sept. 28, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("JinMed" or "the Company") (NASDAQ: ZJYL), aCayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, received a written notification letter ("t...
2023-09-29 04:30
2127
AMRIC, A New Premium Imaging Clinic on Manhattan's Upper East Side Featuring Cutting-Edge Scanners from United Imaging, Opens its Doors
Focusing on every detail, the clinic combines advanced multi-modality technology with highly tailored patient care to bring a new standard of preventive and diagnostic screenings to the center ofNew York City. HOUSTON, Sept. 28, 2023 /PRNewswire/ -- United Imaging, a leading global manufacturer...
2023-09-29 00:00
2099
Origin Agritech Limited Partners with Strategic Investor Relations, LLC to Support its Corporate Communications and Investor Relations Efforts
BEIJING, Sept. 28, 2023 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced that it has retained Strategic Investor Relations, LLC. ("SIR"), a leading boutique investor relations firm. This collaborati...
2023-09-28 23:34
1821
SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medi...
2023-09-28 21:30
1561
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor for the treatm...
2023-09-28 20:00
1394
ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (...
2023-09-28 20:00
2212
Health In Tech Partners With Tall Tree Administrators to Extend Health Insurance Options for Small Businesses
The Collaboration Provides Self-Funded Clients Access to Tailored Health Plans and Ancillary Products STUART, Fla., Sept. 28, 2023 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and re-imagines self-funded health plans, is excited to ann...
2023-09-28 20:00
1309
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ant...
2023-09-28 18:09
1524
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
HONG KONG, Sept. 27, 2023 /PRNewswire/ -- Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azaciti...
2023-09-28 10:07
1651
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
WUXI, China, Sept. 27, 2023 /PRNewswire/ -- September 25th, 2023, BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and muci...
2023-09-28 09:46
1991
Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting
- Lunit's 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeu...
2023-09-27 22:03
1666
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 292 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
[Picked up by 279 media titles]
2024-11-08 20:11
Most Read
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
2024-11-11 21:00
5626
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
2024-11-08 20:11
5553
HOIANA RESORT & GOLF LAUNCHES PREMIUM HOIANA PICKLEBALL COURT
2024-11-08 00:18
5403
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
2024-11-12 09:00
5110